Gyre Therapeutics
Anti-fibrotic/anti-inflammatory drugs, commercialized via majority-owned China subsidiary (Beijing Continent Pharmaceutical / Gyre Pharmaceuticals)
GYRE · Nasdaq · United States
Share price · GYRE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GYRE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+18.7%
- 30 Oct 2026-28.9%
Nothing announced by GYRE that day or the session before.
- 29 Oct 2026-9.6%
Nothing announced by GYRE that day or the session before.
- 28 Oct 2026+8.6%
Nothing announced by GYRE that day or the session before.
- 18 Sep 2026+5.2%
Nothing announced by GYRE that day or the session before.
- 4 Sep 2026+6.5%
- 17 Jul 2026-5.8%
- 2 Jul 2026+12.6%
Nothing announced by GYRE that day or the session before.
- 4 Jun 2026+8.8%
Nothing announced by GYRE that day or the session before.
- 7 May 2026-12.1%
Share of unusual movement by asset
For each asset, the share of GYRE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 28% |
| Sessions with no dated event | — | 72% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Preclinical / Unstaged | Endothelin A receptorSmall molecule | Pulmonary Arterial Hypertension |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $33M | — | $42M+ $16M short-term inv. | $2.5M-$4.0M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $29M | — | $43M+ $14M short-term inv. | $14M-$17M operating cash flow | report ↗ |
| 2026-Q1 | $23M | $6.7M | $38M+ $12M short-term inv. | $9.9M$3.2M operating cash flow | report ↗ |
| 2025-Q3 | $31M | $2.4M | $40M+ $20M short-term inv. | —$4.7M operating cash flow | report ↗ |
| 2025-Q2 | $27M | $3.4M | $36M+ $18M short-term inv. | —$2.1M operating cash flow | report ↗ |
| 2025-Q1 | $22M | $3.1M | $15M+ $15M short-term inv. | —-$0.1M operating cash flow | report ↗ |
| 2024-Q3 | $25M | $2.8M | $16M+ $9.2M short-term inv. | —$1.7M operating cash flow | report ↗ |
| 2024-Q2 | $25M | $3.4M | $16M+ $9.0M short-term inv. | —-$5.5M operating cash flow | report ↗ |
| 2024-Q1 | $27M | $2.2M | $30M+ $7.6M short-term inv. | —$2.9M operating cash flow | report ↗ |
| 2023-Q3 | $32M | $0.4M | $2.2M | $1.6M-$3.2M operating cash flow | report ↗ |
| 2023-Q2 | $29M | $0.3M | $6.9M | $2.5M-$2.5M operating cash flow | report ↗ |
| 2023-Q1 | $25M | $0.6M | $8.1M | —-$6.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $0.8M | $23M+ $0 short-term inv. | $4.9M-$7.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.9M | $75M+ $0 short-term inv. | —-$12M operating cash flow | report ↗ |
| 2022-Q1 | $0.8M | $9.7M | $35M+ $0 short-term inv. | $15M-$12M operating cash flow | report ↗ |
| 2021-Q3 | $2.3M | $20M | $59M+ $5.4M short-term inv. | $25M-$22M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $117M | $14M | $37M+ $15M short-term inv. | —$1.0M operating cash flow | report ↗ |
Gyre Therapeutics reported full-year 2025 revenue of $116.6M, up 10.2% YoY, with R&D spend of $13.7M, up 14.0% YoY. Cash and cash equivalents totaled $37.07M at year-end, while cash, cash equivalents, and short-term and long-term bank deposits were $75.9M. The company reported full-year net income of $9.9M.
Management issued 2026 revenue guidance of $100.5M to $111.0M, representing a YoY decline of approximately 13.8% to 4.8%. Gyre also announced an agreement to acquire Cullgen in an all-stock transaction valued at approximately $300M, expected to close in Q2 2026, reported alignment with China’s CDE on a conditional approval filing for Hydronidone with NDA submission expected in the first half of 2026, completed enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis trial with 272 patients across 18 sites, and anticipates a U.S. IND for Hydronidone in MASH-associated liver fibrosis in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $106M | $12M | $12M+ $15M short-term inv. | —-$3.6M operating cash flow | report ↗ |
| 2023-FY | $113M | $14M | $34M | $21M$26M operating cash flow | report ↗ |
| 2022-FY | $102M | — | $22M+ $0 short-term inv. | $2.1M-$33M operating cash flow | report ↗ |
| 2021-FY | $7.3M | $69M | $44M+ $2.5M short-term inv. | $22M-$84M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 18 sales ($953K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-03 | Kirkby Maxwell · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-08-03 | Weston Claire · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-18 | Ye Weiguo · Chief Operating Officer | Option exercise | 3,000 | $0.75 | $2K | Form 4 |
| 2026-06-18 | Ye Weiguo · Chief Operating Officer | Open-market sale | 3,000 | $6.35 | $19K | Form 4 |
| 2026-06-18 | Ye Weiguo · Chief Operating Officer | Option exercise (derivative) | 3,000 | — | — | Form 4 |
| 2026-06-11 | Ye Weiguo · Chief Operating Officer | Option exercise | 2,800 | $0.75 | $2K | Form 4 |
| 2026-06-11 | Ye Weiguo · Chief Operating Officer | Open-market sale | 2,800 | $6.17 | $17K | Form 4 |
| 2026-06-11 | Ye Weiguo · Chief Operating Officer | Option exercise (derivative) | 2,800 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 3.4M shares ($23.7M, 3.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 984,204 | $6.9M |
| 2 | BlackRock, Inc. | 758,630 | $5.3M |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 431,414 | $3.0M |
| 4 | STATE STREET CORP | 216,326 | $1.5M |
| 5 | SBI Securities Co., Ltd. | 170,837 | $1.2M |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 165,238 | $1.2M |
| 7 | VANGUARD FIDUCIARY TRUST CO | 137,682 | $960K |
| 8 | NORTHERN TRUST CORP | 133,841 | $933K |
| 9 | GOLDMAN SACHS GROUP INC | 73,122 | $510K |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 69,814 | $487K |
| 11 | Bank of New York Mellon Corp | 43,144 | $301K |
| 12 | DIMENSIONAL FUND ADVISORS LP | 25,268 | $176K |
| 13 | ALLIANCEBERNSTEIN L.P. | 21,830 | $154K |
| 14 | STRS OHIO | 21,100 | $147K |
| 15 | UBS Group AG | 21,087 | $147K |